FTC Challenges Private Equity in Health Care: Analyzing Regulatory Scrutiny

The Federal Trade Commission (FTC) under President Trump is intensifying its scrutiny of private equity’s increasing role in the health care sector, taking bold steps to challenge mergers and acquisitions (M&A). The commission has made a landmark move by suing to block a $627 million acquisition of Surmodics, a leading maker of specialized coatings for medical devices, by the private equity firm GTCR. This legal challenge represents the first such FTC action since Trump took office and may signal a shift in how regulatory bodies approach the consolidation of health care companies under private equity ownership. As private equity firms continue to target the health care market, this action could have significant implications for the industry and its future.

FTC’s Challenge to GTCR-Surmodics Acquisition

In a unanimous 4-0 vote, the FTC commissioners moved to prevent the $627 million deal between GTCR and Surmodics, citing anti-competitive concerns. According to the commission, combining the two largest providers of specialized hydrophilic coatings for medical devices would reduce competition in the market, which currently sees both companies fiercely competing for business. Hydrophilic coatings are essential in medical devices such as catheters and guidewires, helping doctors maneuver within tight, critical areas like blood vessels without causing damage.

The

The commission’s move is significant not only because it challenges a high-profile private equity acquisition but also because it underscores the increasing scrutiny of private equity involvement in health care, a sector where lives and livelihoods are at stake. FTC commissioners Rebecca Kelly Slaughter and Alvaro Bedoya voiced their concern, stressing that consolidation in health care markets is particularly alarming because of its potential to negatively impact patient care and treatment costs.

Despite the FTC’s opposition, Surmodics is adamant that the merger will be pro-competitive, and the company is determined to move forward. Surmodics has been in discussions with the FTC for months, trying to reach a resolution that would satisfy regulatory concerns, but the agency’s decision to initiate litigation has sparked disappointment.

What Undercode Says:

Private equity’s growing presence in the health care industry has sparked a broader debate about the long-term effects of consolidation in such a vital sector. On one hand, proponents of private equity argue that these firms can bring efficiency, innovation, and the ability to scale, which can ultimately benefit patients through lower costs, faster delivery, and better products. Private equity investments can help smaller health care companies grow, expand their offerings, and innovate in a competitive landscape. Moreover, merging companies within the same sector may create synergies, improve resource allocation, and help businesses reach economies of scale.

However, critics, like the FTC, worry that the increasing concentration of market power in the hands of a few large players could harm consumers. In health care, where the quality of services directly impacts people’s well-being, the risks associated with reduced competition could outweigh the potential benefits. Consolidation often leads to less choice, higher prices, and diminished quality of care—especially when a few dominant players control essential aspects of the supply chain. The FTC’s challenge is a direct response to these concerns, as it seeks to prevent the creation of monopolies or oligopolies that could harm patients and the broader health care system.

The scrutiny of private equity in health care is part of a larger trend toward regulatory intervention, with a particular focus on “rollups,” a strategy where private equity firms consolidate fragmented markets through multiple small acquisitions. This practice is increasingly seen as a way to accumulate market share quickly and dominate sectors, but it often comes at the expense of competition. As private equity firms continue to target the health care market, regulatory bodies will likely continue to take a more cautious and critical approach.

The Trump administration’s approach to antitrust enforcement could have lasting consequences, particularly as it intersects with the Biden administration’s focus on health care regulation. While private equity deals often bring economic advantages in other sectors, the unique nature of health care—where service quality and accessibility directly affect lives—has made it a contentious area of focus. The FTC’s challenge to the GTCR-Surmodics acquisition signals a more aggressive stance toward private equity firms attempting to consolidate power in health care markets.

As health care continues to evolve under private equity’s influence, it will be crucial to monitor how regulators respond to these increasingly complex transactions. The ongoing regulatory push could redefine the relationship between private equity and health care, influencing how companies structure future acquisitions and the broader landscape of health care delivery.

Fact Checker Results:

The FTC has indeed launched a legal challenge against the GTCR-Surmodics merger, citing anti-competitive concerns.
The proposed merger would give the combined entity control over more than 50% of the hydrophilic coatings market.
Surmodics has stated its commitment to completing the merger, maintaining that it will be pro-competitive.